[New inflammatory bowel disease drugs targeting the inflammatory cascade].
Desreumaux
P
P
Maladies de l'Appareil Digestif et Nutrition, Hôpital Cl.-Huriez, CHRU, 59800 Lille.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D016753:Interleukin-10 / Q000627:therapeutic use; D017370:Interleukin-11 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents; D017370:Interleukin-11; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000069285:Infliximab; D009173:Mycophenolic Acid